Small Molecule API Market Will Hit at A CAGR of 9.1% and To Garner US$ 274.9 Billion by 2026, Says Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Request FREE Sample

Global Small Molecule API Market, by API Type (Artificial, and Natural), by Category (Analgesic, Anesthetics, Anticonvulsants, Antimetabolites, Antibacterial, Alkylating Agents, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 126.6 million in 2017 and is projected to exhibit a CAGR of 9.1% during the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Research and development in API by market players to augment the market growth

Key players in the market are focused on research and development of novel products to address the critical and unmet needs of patients. According to India Brand Equity Foundation (IBEF), investment in research and development by India-based pharmaceutical companies increased (in term of sales) from 5.3% to 8.5% between 2012 and 2018. Similarly, as per the U.S. Food and Drug Administration (FDA), in March 2016, there were around 37 drugs in clinical development for treating serious bacterial infections. These drugs are intended to be primarily launched in the U.S.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/small-molecule-api-market-to-surpass-us-2749-million-by-2026-1370

Moreover, the increasing prevalence of various types of cancers worldwide is expected to boost the market growth. International Agency for Research on Cancer published the GLOBOCAN 2018 report which focuses on geographic variability of cancer incidence and mortality rate across 20 world regions. The report projected 18.1 million new cancer cases (17.0 million excluding non-melanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding non-melanoma skin cancer) in 2018.

Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. In October 2017, CordenPharma announced acquisition of Pfizer Inc., a manufacturing facility of API Hospira in Colorado, U.S. This acquisition strengthened the CordenParma’s position, as a leading Contract Development & Manufacturing Organization (CDMO).

Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2423

Key Takeaways of the Small Molecule API Market:

• The global small molecule API market is expected to exhibit a CAGR of 9.1% during the forecast period owing to the rising prevalence of cancer and other diseases, extensive research and development for API production, and expansion strategies by market players. In October 2016, Cambrex Corporation acquired the 35,000-square-foot High Point site, formerly owned by PharmaCore
• Among API type, the artificial segment held a dominant position in the small molecule API market in 2018 owing to high prevalence of chronic pain diseases worldwide
• Among category, the analgesic segment held the dominant position in the small molecule API market in 2018 as majority of the recent generics launches are in form of sublingual films used in treatment of opioid dependence.
• Key players operating in the global small molecule API market are Siegfried, Sanofi, Johnson Matthey, Mallinckrodt, Noramco, Unichem Laboratories, Arevipharma GmbH, Resonance-labs, Sun Pharmaceutical Industries Ltd., Rusan Pharma, Micro Orgo Chem, and Faran Shimi Pharmaceutical Co.

Have a Look at Related Research Insights: